CM
VYNT

Castleark Management’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Castleark Management’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,243
Closed -$2.81M – 408
2014
Q3 		$2.81M Buy
+1,243
New +$1.78M 0.08% 201
2014
Q2 		– Sell
-1,243
Closed -$2.81M – 344
2014
Q1 		$2.81M Buy
+1,243
New +$3.18M 0.08% 201

Other funds holding VYNT

Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAG
Millrace Asset Group Berwyn, Pennsylvania $98.4M AUM 63.71% 1-Year Est. Return
GMCM
Gruber & McBaine Capital Management San Francisco, California $369M AUM 12.23% 1-Year Est. Return
SIM
SSI Investment Management Los Angeles, California $1.72B AUM 7.09% 1-Year Est. Return
SCM
Sterneck Capital Management Kansas City, Missouri $233M AUM 21.98% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DM
Diker Management New York $130M AUM 97.77% 1-Year Est. Return

Castleark Management's VYNT Position: Q4 2014 in Review

Castleark Management sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q4 2014, closing a stake of 1,243 shares — an estimated $2.81M sold.

Castleark Management first reported a position in VYNT in Q1 2014 and held it in 2 quarters. The position peaked at $2.81M in Q3 2014. 31 funds tracked by Wall St. Rank hold VYNT as of Q4 2014.

  • Castleark Management reported no remaining Vyant Bio, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • Castleark Management sold 1,243 Vyant Bio, Inc. Common Stock shares in Q4 2014, an estimated $2.81M.
  • Castleark Management first reported a position in Vyant Bio, Inc. Common Stock in Q1 2014 and held it in 2 quarters.
  • Castleark Management's Vyant Bio, Inc. Common Stock position peaked at $2.81M in Q3 2014.
  • 31 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q4 2014.

Based on Castleark Management's 13F filing for Q4 2014, filed 10 Feb 2015.